Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.
about
Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and PreventionBiosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivoIdentification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductaseKinetics of metoprine, a lipid-soluble antifolate.A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal modelsSingle dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers.Excretion of chloroquine, dapsone and pyrimethamine in human milkSalivary elimination of pyrimethamine.Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazineLevels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study GroupEffect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting.Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDSPopulation pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.
P2860
Q26768143-C650C5D4-0C2E-4DFD-A3C7-955C1BA3EE86Q28270463-0F0F107B-E0BF-43D6-81D6-2CCB58B167EAQ28378350-4B45B98F-40D1-4127-AA18-BC76798E5718Q33486600-3DB2E9CC-7EFF-4D96-9926-A5A19F471ABCQ33552774-61AF8D43-5215-42F6-9057-48C1DA659CE1Q34234969-556F5D96-26BE-4687-AE9B-E24AF162465AQ34397470-46731988-4BE6-41DD-8664-FE7BFAF147AFQ34448267-EE792123-271E-4914-A71D-2D709C17D1BEQ34448826-2B823AEF-6145-4CCD-A389-79447C40157CQ34519462-7F18FBD8-680B-4209-929F-D03CC5321A76Q35110989-2EE7D587-820D-413A-B7B2-B9E98672B6DCQ35836203-8817C917-E58F-4169-94BC-30E61D7B5ADDQ36558437-11DC8804-3E96-4398-BF08-EB7D7E2EDE49Q36640235-4F9AEE6E-713A-49D0-84E7-E7F85C453C44Q39782411-09560C4B-5A46-4563-ACCA-2B4D6C759CCFQ40165651-A7464CAE-E741-4040-A456-94FA0D81819A
P2860
Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@en
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@nl
type
label
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@en
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@nl
prefLabel
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@en
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@nl
P2093
P1476
Lipid-soluble inhibitors of di ...... rine in the rat, dog, and man.
@en
P2093
C A Nichol
D R Stickney
J C Cavallito
R L Deangelis
W D Brenckman
W S Simmons
P304
P577
1978-05-01T00:00:00Z